SREBF1 and fatty liver disease: This highlights the delicate position of SHP in the development of hepatic steatosis, inhibiting RXR/LXR-ChREBP/SREBP-1c-mediated DNL, while at the same time promoting DNL via the HES6-HNF4α-PPARγ pathway.